Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,690Revenue $M147Net Margin (%)-55.0Z-Score9.2
Enterprise Value $M7,333EPS $-0.6Operating Margin %-45.3F-Score2
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-54.7Higher ROA y-yN
Price/Book22.210-y EBITDA Growth Rate %0Quick Ratio6.3Cash flow > EarningsY
Price/Sales44.55-y EBITDA Growth Rate %28.7Current Ratio6.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-11.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-25.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M118ROI % (ttm)-13.6Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 65.09107%Sold Out0
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 65.09107%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 65.0935%New holding, 45251 sh.45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 65.0935%New holding, 5539 sh.5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 65.09630%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 65.09607%New holding, 22300 sh.22,300
ISISJean-Marie Eveillard 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 65.09587%Sold Out0
ISISJean-Marie Eveillard 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 65.09643%New holding, 100000 sh.100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 65.09643%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 65.09556%New holding, 16100 sh.16,100
ISISJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 65.09531%Sold Out0
ISISJean-Marie Eveillard 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 65.09445%New holding, 50000 sh.50,000
ISISKen Fisher 2008-12-31 Sold Out $10.37 - $15.82
($12.96)
$ 65.09402%Sold Out0
ISISKen Fisher 2008-09-30 Buy $14.24 - $19.08
($16.9)
$ 65.09285%New holding, 10050 sh.10,050
ISISJean-Marie Eveillard 2007-12-31 Sold Out $15.4 - $17.69
($16.7)
$ 65.09290%Sold Out0
ISISJean-Marie Eveillard 2007-09-30 Buy $9.74 - $14.97
($12.1)
$ 65.09438%New holding, 25000 sh.25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
O'NEIL PATRICK R.SVP, Legal & General Counsel 2014-12-01Sell1,500$51.2127.1view
ISIS PHARMACEUTICALS INC10% Owner 2014-11-03Sell1,279,411$15.94308.34view
O'NEIL PATRICK R.SVP, Legal & General Counsel 2014-11-03Sell1,500$46.1740.98view
PARSHALL B LYNNECOO & Secretary 2014-10-30Sell11,071$45.1244.26view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-10-24Sell113,084$14.02364.27view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-10-24Sell113,084$14.02364.27view
CROOKE STANLEY TChairman and CEO 2014-10-23Sell14,600$42.2254.17view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-10-17Sell12,100$6.74865.73view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-10-10Sell10,050$6.56892.23view
CROOKE STANLEY TChairman and CEO 2014-10-03Sell36,000$38.5268.98view

Press Releases about ISIS :

    Quarterly/Annual Reports about ISIS:

    News about ISIS:

    Articles On GuruFocus.com
    Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
    Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
    Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
    Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
    Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
    Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 


    More From Other Websites
    Nasdaq stocks posting largest percentage increases Dec 19 2014
    Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
    Jim Cramer's Top Stock Picks: BA MMM ISIS Q Dec 19 2014
    Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally Dec 18 2014
    Cramer: One of the most exciting stocks I've seen Dec 18 2014
    Isis Pharmaceuticals' game-changer drug Dec 18 2014
    Stock Pops & Drops: SPWR, CROX, GOOGL & ISIS Dec 16 2014
    Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy... Dec 16 2014
    Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy... Dec 16 2014
    Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices Dec 10 2014
    ISIS Jumps on Positive Results for Venous Thrombosis Drug Dec 09 2014
    Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4% Dec 08 2014
    Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences,... Dec 08 2014
    Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous... Dec 07 2014
    Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous... Dec 07 2014
    Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award Dec 05 2014
    Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award Dec 05 2014
    Earnings Estimates Moving Higher for Isis Pharmaceuticals (ISIS): Time to Buy? Dec 04 2014
    ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England... Dec 03 2014
    ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England... Dec 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK